ReviewRheumatology international2021
Comorbidities in rheumatic diseases need special consideration during the COVID-19 pandemic.
Review in Rheumatology international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 74 citations in OpenAlex.
- Real-world immune response to SARS-CoV-2 vaccination in Thai patients with systemic lupus erythematosus: a cross-sectional observational study.Lupus science & medicine · 2025Observational
- Low vaccination rates and awareness status in patients with rheumatoid arthritis: a nationwide cross-sectional survey study.Rheumatology international · 2025Article
- Late-onset Systemic Lupus Erythematosus.Rheumatology international · 2025Review
- COVID-19 incidence among Kenyan patients with and without inflammatory rheumatic disease.Journal of public health in Africa · 2025Article
- Healthcare professionals' knowledge and perceptions of post-stroke rehabilitation in the peripandemic period: an online cross-sectional survey.Rheumatology international · 2024Article
- The interplay between rheumatic diseases and pulmonary health.Rheumatology international · 2024Review
- Post-stroke rehabilitation in the peri-pandemic COVID-19 era.Rheumatology international · 2024Review
- Adoption rates of recommended vaccines and influencing factors among patients with inflammatory arthritis: a patient survey.Rheumatology international · 2024Article
- Correlates of breakthrough COVID-19 in vaccinated patients with systemic sclerosis: survival analysis from a multicentre international patient-reported survey.Rheumatology international · 2024Article
- Diabetes mellitus in rheumatic diseases: clinical characteristics and treatment considerations.Rheumatology international · 2023Review
- Cardiovascular health worsening in patients with autoimmune rheumatological diseases during the COVID-19 pandemic.Clinical rheumatology · 2023Review
- Acute COVID-Related Hip Arthritis. Case Report and Literature Review.Journal of orthopaedic case reports · 2023Article
- Correlates of breakthrough Omicron (B.1.1.529) infections in a prospective cohort of vaccinated patients with rheumatic diseases.Rheumatology international · 2023Article
- Comorbidities in the COVID-19 Pandemic: Scopus-Based Bibliometric Analysis.Journal of Korean medical science · 2023Article
- Article
- Physicians' perceptions about antineutrophil cytoplasmic antibody-associated vasculitis: an online survey report in the time of the COVID-19 pandemic.Clinical rheumatology · 2023Article
- Post Covid-19 Reactive Arthritis in Two Stem Cell Transplant Recipients.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2023Article
- Interplay of diabetes mellitus and rheumatic diseases amidst the COVID-19 pandemic: influence on the risk of infection, outcomes, and immune responses.Clinical rheumatology · 2022Review
- Effectiveness and safety of COVID-19 vaccines in patients with diabetes as a factor for vaccine hesitancy.World journal of diabetes · 2022Review
- COVID-19 among patients with giant cell arteritis: a single-centre observational study from Slovenia.Clinical rheumatology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Comorbidities in rheumatic and musculoskeletal diseases (RMDs) not only increase morbidity and mortality but also confound disease activity, limit drug usage and increase chances of severe infections or drug-associated adverse effects. Most RMDs lead to accelerated atherosclerosis and variable manifestations of the metabolic syndrome. Literature on COVID-19 in patients with RMDs, and the effects of various comorbidities on COVID-19 was reviewed. The initial data of COVID-19 infections in RMDs have not shown an increased risk for severe disease or the use of different immunosuppression. However, there are some emerging data that patients with RMDs and comorbidities may fare worse. Various meta-analyses have reiterated that pre-existing hypertension, cardiovascular disease, stroke, diabetes, chronic kidney disease, heart failure, lung disease or obesity predispose to increased COVID-19 mortality. All these comorbidities are commonly encountered in the various RMDs. Presence of comorbidities in RMDs pose a greater risk than the RMDs themselves. A risk score based on comorbidities in RMDs should be developed to predict severe COVID-19 and death. Additionally, there should be active management of such comorbidities to mitigate these risks. The pandemic must draw our attention towards, and not away from, comorbidities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.